TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Faruqi & Faruqi, Llp
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Tvardi Therapeutics experienced significant stock decline after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.

Insights
TVRD   negative

Stock plummeted over 80% after unsuccessful clinical trial results, with the study failing to meet its primary objectives and demonstrating ineffective treatment outcomes